Protocol · Mental Health
Schizophrenia Protocol
Sarcosine and Glycine are the core of this stack, with 5 supporting supplements. Each row gives the amount the protocol lists and the grade our evidence database holds for that supplement in Schizophrenia.
We are re-verifying the studies cited on protocol pages; only confirmed citations are shown.
The stack
7 supplements · 5 graded · 1 graded A · 1 confirmed study
| Grade | Supplement | Amount listed | Why it’s in the stack | Evidence on file |
|---|---|---|---|---|
| Primary stackThe core of this protocol | ||||
| Sarcosine | Amount listed: 2 g daily | Glycine transporter-1 inhibitor that enhances NMDA receptor function to improve negative and cognitive symptoms
| Grade A for Schizophrenia symptoms1 study · 183 people | |
| Glycine | Amount listed: 0.4–0.8 g/kg/day (typically 30–60 g daily) | NMDA receptor co-agonist that enhances glutamatergic neurotransmission to improve negative symptoms
| Grade B for Schizophrenia symptoms3 studies · 50 people | |
| Supporting stackListed as additions to the core | ||||
| D-Serine | Amount listed: 30–60 mg/kg/day (typically 2–4 g daily) | NMDA receptor co-agonist with higher potency than glycine; improves negative and cognitive symptoms
| Grade B for Cognition262 people | |
| Omega-3 Fatty Acids | Amount listed: 2–4 g EPA/DHA daily | May improve membrane fluidity and reduce inflammation; modest effects on symptoms and prevention
| Not graded yet | |
| N-Acetylcysteine (NAC) | Amount listed: 2,000 mg daily | Modulates glutamate via cystine-glutamate antiporter and provides antioxidant support
| Grade D for Processing Speed136 people | |
Confirmed studies for N-Acetylcysteine (NAC) (titles as PubMed lists them) | ||||
| Folate/Methylfolate | Amount listed: 2–15 mg daily (as L-methylfolate for those with MTHFR variants) | Supports methylation pathways; deficiency common in schizophrenia; may improve negative symptoms
| Grade C for Cognition1 study · 55 people | |
| Vitamin D | Amount listed: 2,000–4,000 IU daily (target 40–60 ng/mL) | Deficiency associated with schizophrenia risk and severity; supports neuroprotection and immune function | Not graded yet | |
How this protocol works
In plain language
Schizophrenia is a serious mental illness affecting about 1% of the population. While antipsychotic medications effectively treat positive symptoms (hallucinations, delusions), they have limited effect on negative symptoms (social withdrawal, lack of motivation, reduced emotional expression) and cognitive impairment—which significantly impact quality of life. This protocol focuses on supplements that may help with these difficult-to-treat symptoms, always as adjuncts to standard psychiatric care.
IMPORTANT: These supplements are meant to complement, not replace, antipsychotic medications and psychiatric care. Never stop or adjust medications without consulting your psychiatrist.
- Sarcosine is the most promising supplement for schizophrenia. It works by blocking the glycine transporter-1 (GlyT-1), which increases glycine levels at the NMDA receptor. The NMDA receptor hypothesis of schizophrenia suggests that underactivity of this receptor contributes to negative and cognitive symptoms. Studies show sarcosine can improve negative symptoms, cognitive function, and overall functioning when added to antipsychotics. It should NOT be used with clozapine (may reduce clozapine's effectiveness).
- Glycine directly activates the NMDA receptor as a co-agonist. High doses are needed because most glycine doesn't reach the brain. Studies show it can improve negative symptoms when added to antipsychotics (except clozapine). The large doses required (30-60g/day) can be impractical and cause GI issues.
- D-Serine is another NMDA receptor co-agonist, more potent than glycine. It may improve negative and cognitive symptoms. However, there are theoretical concerns about kidney toxicity at high doses (though human studies haven't confirmed this).
- Omega-3 Fatty Acids have shown particular promise in early-stage psychosis and those at ultra-high risk for developing schizophrenia. One landmark study found omega-3s significantly reduced the conversion to full psychosis in at-risk youth. Effects in established schizophrenia are more modest but may help with overall symptom burden.
- N-Acetylcysteine (NAC) modulates glutamate signaling through the cystine-glutamate antiporter and provides powerful antioxidant support. It may help with negative symptoms and reduce the severity of positive symptoms. It's also been studied for improving overall symptom scores.
- Folate/Methylfolate deficiency is common in schizophrenia and may contribute to negative symptoms. Supplementation, particularly with methylfolate (which bypasses the common MTHFR genetic variation), may improve negative symptoms in those with low folate status or specific genetic variants.
- Vitamin D deficiency is very common in schizophrenia (possibly due to reduced sun exposure) and has been linked to both disease risk and severity. While not directly therapeutic, correcting deficiency is reasonable.
Expected timeline: NMDA-targeting supplements (sarcosine, glycine, D-serine) may show effects within 4-8 weeks. NAC: 8-12 weeks. Omega-3s: variable, potentially longer in early intervention. Always monitor symptoms closely with your psychiatric team.